Related Experiment Video

Updated: Jun 22, 2026

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Molecular targets for treatment of inflammatory breast cancer

Hideko Yamauchi1, Massimo Cristofanilli, Seigo Nakamura

  • 1St Luke's International Hospital, Tokyo, Japan.

Nature Reviews. Clinical Oncology
|May 27, 2009
PubMed

Insights

Despite advances, inflammatory breast cancer (IBC) outcomes remain poor. Targeting angiogenesis, cell proliferation (like HER2), and metastasis offers promising therapeutic strategies for improved patient results.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Inflammatory breast cancer (IBC) presents poor long-term outcomes despite combined-modality treatments.
  • Targeting vasculolymphatic processes, including angiogenesis, shows potential for IBC treatment.

Purpose of the Study:

  • To review key molecular pathways—vasculolymphatic, cell proliferation, and metastatic—as potential therapeutic targets for inflammatory breast cancer.
  • To highlight the significance of targeting human epidermal growth factor receptor 2 (HER2) in improving IBC patient outcomes.

Main Methods:

  • Review of current literature on targeted therapies for inflammatory breast cancer.
  • Analysis of therapeutic strategies focusing on angiogenesis, lymphangiogenesis, vasculogenesis, cell proliferation, and metastasis.

Main Results:

  • Targeting angiogenesis demonstrates potential through direct antiangiogenic and synergistic antitumor effects.
  • Therapies targeting cell proliferation pathways, particularly human epidermal growth factor receptor 2 (HER2), have shown clinical success.
  • Metastatic pathways are implicated in the aggressive nature of IBC and warrant further investigation.

Conclusions:

  • Targeting angiogenesis, cell proliferation (especially HER2), and metastatic pathways represents a promising avenue for improving inflammatory breast cancer treatment.
  • Further research into the unique molecular characteristics of IBC is crucial for developing more effective therapies and improving patient outcomes.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...